Pasithea Therapeutics Corp. Common Stock

Pasithea Therapeutics Corp. a biotechnology company engages in research and discovery of treatments for Central Nervous System disorders RASopathies and other diseases. It operates through two segments Therapeutics and Clinics. The company provides business support services to anti-depression clinics entities and registered healthcare providers. Its lead product candidate PAS-004 a next-generation mitogen-activated protein kinase or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies including neurofibromatosis type 1 and Noonan syndrome as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003 to treat amyotrophic lateral sclerosis; PAS-002 for the treatment multiple sclerosis; and PAS-001 to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach Florida.